GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 134
- Registration Number
- NCT01522651
- Locations
- 🇬🇧
Investigational Site, London, England, United Kingdom
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
- Conditions
- Pancreatic CancerMetastatic Pancreatic AdenocarcinomaMetastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2012-01-16
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT01510561
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of North Carolina Medical Center, Chapel Hill, North Carolina, United States
🇺🇸Goshen Center for Cancer Care, Goshen, Indiana, United States
Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
- Conditions
- Acquired Immunodeficiency SyndromeHIV Infections
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 279
- Registration Number
- NCT01497899
- Locations
- 🇺🇸
Kaiser Permanente, Los Angeles, California, United States
🇺🇸Gary J. Richmond,M.D.,P.A., Fort Lauderdale, Florida, United States
🇺🇸Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States
Phase 3 Study of Sofosbuvir and Ribavirin
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 527
- Registration Number
- NCT01497366
- Locations
- 🇺🇸
Peter J. Ruane, M.D. Inc., Los Angeles, California, United States
🇺🇸AIDS Research Consortium of Atlanta, Inc., Atlanta, Georgia, United States
🇺🇸Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
Open-Label Hepatic Impairment Study
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT01497327
Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
- Conditions
- Acquired Immunodeficiency SyndromeHIV Infections
- Interventions
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 439
- Registration Number
- NCT01495702
- Locations
- 🇺🇸
Anthony Mills MD Inc, Los Angeles, California, United States
🇺🇸Atlanta ID Group, PC, Atlanta, Georgia, United States
🇺🇸Saint Michael's Medical Center, Newark, New Jersey, United States
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 431
- Registration Number
- NCT01494987
- Locations
- 🇺🇸
Clinical Research Advantage/Desert Clinical Research, LLC, Mesa, Arizona, United States
🇺🇸Desert Sun Clinical Research, LLC, Tucson, Arizona, United States
🇺🇸Southland Clinical Research Center, Inc., Fountain Valley, California, United States
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2011-11-24
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 266
- Registration Number
- NCT01479465
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸West Michigan Cancer Center, Kalamazoo, Michigan, United States
🇺🇸Providence Saint Joseph Medical Center-Disney Family Cancer Center, Burbank, California, United States
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
- Conditions
- HIV InfectionsAcquired Immunodeficiency Syndrome
- Interventions
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 438
- Registration Number
- NCT01475838
- Locations
- 🇺🇸
Peter J. Ruane, M.D., Inc., Los Angeles, California, United States
🇺🇸OASIS Clinic, Los Angeles, California, United States
🇺🇸Gordon Crofoot Md, Pa, Houston, Texas, United States
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 465
- Registration Number
- NCT01472185
- Locations
- 🇺🇸
Thunderbird Internal Medicine/Clinical Research Advantage, Glendale, Arizona, United States
🇺🇸North Central Arkansas Medical Associates, Mountain Home, Arkansas, United States
🇺🇸Desert Sun Clinical Research, LLC, Tucson, Arizona, United States